Federal Law and Dispensaries: The Legal Conflict Explained

Cannabis dispensaries operate inside one of the most unusual legal structures in American regulatory history — simultaneously licensed and taxed by state governments while remaining prohibited under federal law. That collision isn't abstract. It shapes everything from how dispensaries store cash to whether a landlord can legally rent them space. The conflict runs deep, and understanding its structure helps explain why dispensary operations look nothing like other licensed retail businesses.

• Definition and Scope
• Core Mechanics or Structure
• Causal Relationships or Drivers
• Classification Boundaries
• Tradeoffs and Tensions
• Common Misconceptions
• Key Operational Checkpoints
• Reference Table: Federal vs. State Cannabis Law
• References

Definition and Scope

The conflict begins with a single federal statute. Under the Controlled Substances Act of 1970 (21 U.S.C. § 801 et seq.), cannabis is classified as a Schedule I controlled substance — the most restrictive category, reserved for drugs the Drug Enforcement Administration (DEA) considers to have no accepted medical use and a high potential for abuse. Schedule I status places cannabis alongside heroin and above substances like fentanyl and methamphetamine, which sit at Schedule II.

That classification has never changed, regardless of what 38 states (and Washington D.C.) have done legislatively to authorize medical cannabis programs, or what 24 states have done to legalize adult-use recreational sales (NCSL, State Medical Cannabis Laws). State law can authorize a dispensary. Federal law does not recognize that authorization as a defense to federal prosecution.

The scope of affected operations is wide. The federal prohibition touches banking access, federal tax treatment, employment law, housing eligibility, firearms purchases, and immigration status — all of which flow directly from Schedule I classification, not from any additional state-level restriction.

For a broader orientation to how dispensaries fit into the national regulatory landscape, the dispensary authority overview provides helpful structural context.

Core Mechanics or Structure

The structural source of the conflict is the Supremacy Clause of the U.S. Constitution (Article VI, Clause 2), which establishes that federal law is the supreme law of the land when it conflicts with state law. Ordinarily, that principle would make state cannabis legalization impossible to sustain. What keeps the system functioning is a combination of prosecutorial discretion and appropriations riders, not any formal legal resolution.

The Cole Memorandum (issued by Deputy Attorney General James Cole in 2013) directed federal prosecutors to deprioritize enforcement against cannabis businesses operating in compliance with state law, provided they met eight specific criteria including preventing sales to minors and keeping cannabis revenues from criminal enterprises. The Department of Justice rescinded that memo in January 2018 under Attorney General Jeff Sessions — though in practice, large-scale federal prosecution of state-licensed dispensaries remained rare.

Congressional appropriations riders have played a more durable role. Since fiscal year 2015, Congress has annually passed the Rohrabacher-Blumenauer amendment (later known as the Joyce-Blumenauer amendment), which prohibits the Department of Justice from using appropriated funds to interfere with state medical cannabis programs (Congress.gov). The protection is narrow — it covers medical programs only, requires annual renewal, and has been interpreted by courts as shielding state-compliant conduct from federal prosecution, not from federal civil law.

The tax consequence may be the most quietly devastating mechanic. Internal Revenue Code Section 280E, enacted in 1982, prohibits businesses trafficking in Schedule I or II substances from deducting ordinary business expenses on federal tax returns. A dispensary paying rent, salaries, and utilities cannot deduct those costs the way any other retailer would. The effective federal tax rate for cannabis businesses operating under 280E regularly exceeds 70%, according to cannabis industry tax analyses — a structural penalty with no parallel in licensed retail (IRS Publication 535).

Causal Relationships or Drivers

The persistence of the conflict is not accidental. Three distinct forces sustain it.

First, the reclassification process under the Controlled Substances Act requires coordination between the DEA and the Department of Health and Human Services (HHS). In August 2023, HHS formally recommended that cannabis be rescheduled from Schedule I to Schedule III — a move that, if finalized by the DEA, would remove the Section 280E tax burden but would not legalize recreational sales ([HHS, August 2023 recommendation letter, widely reported via DEA docket]). The DEA retains final authority over scheduling decisions and has historically moved slowly on cannabis reclassification requests.

Second, federal banking law creates structural cash dependency. The Bank Secrecy Act requires financial institutions to file Suspicious Activity Reports for transactions they know or suspect involve proceeds of federal crimes. Cannabis sales are federal crimes. Banks and credit unions that service dispensaries accept legal risk, and most federally chartered institutions have declined to do so. The SAFE Banking Act — which would provide safe harbor for financial institutions serving state-licensed cannabis businesses — passed the U.S. House of Representatives 7 times between 2019 and 2022 without Senate passage (American Bankers Association, SAFE Banking tracking).

Third, federal employment and housing law create collateral consequences for individual consumers and workers. Federal employees, military personnel, and public housing residents can face adverse action for cannabis use that is fully legal under state law. The regulatory context for dispensaries covers how state licensing frameworks attempt to navigate around these federal pressure points.

Classification Boundaries

The federal conflict does not operate uniformly across all cannabis-adjacent activity. The legal exposure varies sharply by substance, business activity, and geography.

Hemp-derived CBD sits in a different legal category. The Agriculture Improvement Act of 2018 (the 2018 Farm Bill, 7 U.S.C. § 1639o) removed hemp — defined as cannabis with a delta-9 THC concentration of 0.3% or less on a dry weight basis — from the Controlled Substances Act entirely. Products derived from compliant hemp are federally legal to sell, though the FDA retains authority over hemp-derived CBD in food and dietary supplements.

THC products above the 0.3% threshold remain Schedule I regardless of state law. A dispensary selling THC products is, under federal law, engaging in drug trafficking.

Interstate commerce is an absolute boundary. Cannabis cannot legally cross state lines even between two states with full legalization — doing so constitutes federal drug trafficking with felony penalties. This explains why each state's cannabis supply chain must remain entirely within state borders, and why national brands operate through state-by-state licensing arrangements rather than direct interstate distribution.

Tradeoffs and Tensions

The federal-state conflict creates genuine tradeoffs that play out in operational decisions every licensed dispensary makes. Cash-intensive operations are a security liability — dispensaries hold substantially more physical currency than comparable retailers because banking access remains limited, making them targets for robbery. The dispensary security requirements framework that most states mandate exists, in part, as a direct response to this federally induced cash dependency.

The tax burden under Section 280E simultaneously concentrates pressure on pricing and suppresses employment compensation. Dispensaries cannot deduct wages as a business expense — only cost of goods sold (COGS) can be deducted, under a narrow interpretation sustained by Tax Court decisions including Harborside Health Center v. Commissioner (T.C. Memo 2020-85). That asymmetry pushes dispensary operators toward inventory management strategies that would seem unusual in any other retail context.

Federal rescheduling to Schedule III would resolve the 280E issue but would introduce FDA regulatory authority over cannabis products — a framework the agency has not yet established and which could impose clinical testing requirements, labeling mandates, and manufacturing standards substantially more demanding than current state-level requirements.

Common Misconceptions

Misconception: State legalization makes cannabis federally legal.
It does not. State law cannot override the Controlled Substances Act. State legalization creates a legal permission under state law only; it does not grant immunity from federal prosecution.

Misconception: The Cole Memo protected dispensaries.
The Cole Memo was a prosecutorial guidance document, not a law or regulation. It was rescinded in January 2018 and carried no legal force in any court proceeding. Federal prosecutors retained — and retain — full authority to prosecute state-licensed cannabis businesses.

Misconception: Banking is unavailable to all dispensaries.
Approximately 800 banks and credit unions reported providing services to cannabis-related businesses as of the Financial Crimes Enforcement Network's (FinCEN) March 2023 Marijuana Banking Update. Most are small state-chartered institutions or credit unions, and services remain limited and expensive compared to standard commercial banking.

Misconception: Rescheduling to Schedule III would legalize dispensaries federally.
Schedule III reclassification would remove cannabis from the most restrictive category and eliminate the 280E tax penalty, but would not legalize retail cannabis sales. Dispensaries would still require DEA registration and FDA compliance — neither of which exists in any functional form for cannabis retail as of the date of HHS's 2023 recommendation.

Key Operational Checkpoints

The following represent the distinct points in dispensary operations where federal law creates direct legal exposure or compliance complexity.

1. Business formation — Federal prohibition affects access to Small Business Administration loans, federal trademarks, and bankruptcy protection. Cannabis businesses cannot file for Chapter 11 bankruptcy reorganization in federal court.
2. Banking and merchant services — Each financial relationship requires institutional risk assessment against Bank Secrecy Act obligations. Dispensary banking arrangements, explored in depth at dispensary banking and payments, typically involve enhanced due diligence fees and limited services.
3. Federal tax filing — Section 280E compliance requires careful separation of COGS from other operating expenses. Misclassification is an audit trigger.
4. Employment — Federal contractors, military personnel, and employees subject to federally mandated drug testing cannot consume cannabis without employment consequences, regardless of state law.
5. Real property — Landlords with federally backed mortgages technically risk loan default by leasing to cannabis businesses. Many landlords charge premium rents to offset this perceived risk.
6. Interstate activity — Any cannabis crossing a state line — including for laboratory testing — constitutes federal trafficking. All supply chain activity must be confirmed as intrastate.
7. Federal firearms law — Under 18 U.S.C. § 922(g)(3), unlawful users of controlled substances are prohibited from possessing firearms. The ATF's Form 4473 explicitly asks purchasers about cannabis use, and cannabis consumers in legal states face potential federal firearms disqualification.

Reference Table: Federal vs. State Cannabis Law